Top MASH Drug Companies in 2026: Madrigal, Novo Nordisk, Boehringer Ingelheim, Akero, and 89bio Shape the Treatment Landscape

NASH/MASH Treatment Market Company Research Insight

The NASH/MASH treatment market has finally moved from pipeline anticipation into commercial reality. For years, companies chased a large patient pool with no approved drug pathway. That created one of the more frustrating areas in metabolic disease drug development. Plenty of science. Plenty of trial activity. Very little commercial certainty.

That changed with the approval of resmetirom. According to DataM Intelligence, the NASH/MASH Treatment Market reached US$ 8.13 billion in 2025 and is expected to reach US$ 40.95 billion by 2035, growing at a CAGR of 17.55% during 2026 to 2035. The market is segmented by drug, stage, age group, gender and region, with key drug categories including Resmetirom, Lanifibranor, Semaglutide, Survodutide, Pegozafermin, Efruxifermin, Denifanstat and others.

The competitive landscape is now split between liver directed drugs, metabolic therapies and fibrosis focused candidates. Madrigal has the first mover advantage with Rezdiffra. Novo Nordisk brings scale through semaglutide and its obesity diabetes franchise. Boehringer Ingelheim is pushing survodutide with breakthrough designation. Akero and 89bio are trying to prove that FGF21 based therapies can become serious competitors. Inventiva, Sagimet and other smaller biotechs are trying to carve out differentiated positions before larger pharma companies crowd the space.

The commercial challenge is not only drug efficacy. Diagnosis is still a bottleneck. MASH patients often move through primary care, endocrinology, obesity care, gastroenterology and hepatology before treatment decisions become clear. DataM identifies Stage 2 to 3 fibrosis as the dominant commercial segment, valued at US$ 3,237.06 million in 2024 and expected to reach US$ 19,391.01 million by 2032, growing at a CAGR of 27.2%.

  Request for Exclusive Sample on NASH/MASH Treatment Market

Top 10 Companies Analysis

Madrigal Pharmaceuticals

Madrigal is the company that opened the market. Its drug Rezdiffra, or resmetirom, became the first FDA approved therapy for adult patients with MASH and moderate to advanced fibrosis. DataM notes that the FDA approved Rezdiffra in March 2024 for adults with noncirrhotic MASH and F2 to F3 fibrosis.

That gives Madrigal a powerful first mover position. It can shape physician education, payer discussions and treatment pathway design before the market becomes crowded. The advantage is real.

The risk is also real. MASH is a large population market, which means payers will be careful. Madrigal needs to convert approval into sustained diagnosis, prescription and reimbursement. The company is no longer only proving science. It is proving launch execution.

Novo Nordisk

Novo Nordisk is one of the most dangerous competitors in the MASH market because it brings commercial scale from obesity and diabetes. That matters because many MASH patients have obesity, insulin resistance or type 2 diabetes.

DataM identifies GLP 1 based MASH treatment as a fast growing use case, noting that semaglutide creates a treatment pathway where liver improvement and metabolic control can be addressed through one therapeutic platform.

Novo’s strength is physician familiarity. Endocrinologists already understand GLP 1 therapy. Patients know the brands. Payers understand the category, even if they do not always like the cost. The challenge will be proving liver specific value strong enough to compete with liver directed drugs in F2 to F3 patients.

Boehringer Ingelheim

Boehringer Ingelheim is becoming more important through survodutide, a GLP 1 and glucagon receptor agonist. DataM notes that survodutide received US FDA Breakthrough Therapy designation in October 2024 for adults with MASH and moderate to advanced fibrosis.

Survodutide sits in the attractive overlap between metabolic disease and liver disease. That is a good place to be. MASH is rarely an isolated liver problem. It usually lives inside obesity, diabetes and broader metabolic dysfunction.

Boehringer’s advantage is that it has the resources to run large trials and build a global launch strategy. The question is differentiation. In a market with semaglutide, tirzepatide interest and liver directed agents, survodutide needs to show a clear clinical reason to be chosen.

Akero Therapeutics

Akero is one of the most closely watched smaller biotechs in MASH because of efruxifermin, an FGF21 analog. DataM highlights efruxifermin as one of the late stage pipeline assets attracting attention in the market.

The FGF21 mechanism is interesting because it targets metabolic dysfunction, liver fat reduction and fibrosis related endpoints. Akero’s opportunity is to show that it can deliver meaningful liver benefit in the population that matters most commercially.

The challenge is scale. Smaller biotechs can win on data, but launches in MASH are expensive. Physician education, payer access and diagnostic pathway support require capital and partnerships. Akero may need commercial support if it wants to compete against larger companies.

89bio

89bio is another major FGF21 player through pegozafermin. Its role in the market is similar to Akero’s in one sense, but the companies will need to differentiate on efficacy, safety, dosing, tolerability and target patient fit.

DataM lists pegozafermin among the key drug categories in the market and identifies FGF21 candidates as high value assets because they target metabolic dysfunction and liver injury through a distinct pathway.

89bio’s opportunity sits in fibrosis improvement and metabolic liver correction. The risk is that promising midstage or late stage data must translate into registrational success and payer confidence. MASH has punished many developers before. Investors remember that.

Inventiva

Inventiva is developing lanifibranor, one of the better known non GLP 1 candidates in the MASH pipeline. DataM lists Lanifibranor as a key drug segment in the NASH/MASH treatment market.

Inventiva’s position is built around differentiation. It is not trying to win as another incretin therapy. That could help if physicians want liver and fibrosis targeted options outside weight loss driven mechanisms.

The problem is commercial weight. Inventiva is smaller than the large pharma competitors moving toward MASH. Even with strong clinical positioning, it may need partners, careful launch focus or a defined niche in the treatment pathway.

Sagimet Biosciences

Sagimet is relevant through denifanstat, a fatty acid synthase inhibitor. DataM includes Denifanstat among the key drug categories in the market.

The company’s appeal is mechanism differentiation. MASH is biologically complex, and no single mechanism is likely to cover every patient profile. Denifanstat could be positioned for patients where liver fat production and metabolic liver injury are central.

Sagimet’s challenge is the same as most focused biotechs. It needs strong data, clear patient targeting and a credible route to commercialization. In a market becoming crowded with GLP 1, FGF21 and THR beta approaches, differentiation has to be obvious.

Chia Tai Tianqing Pharmaceutical Group

Chia Tai Tianqing is listed by DataM as one of the emerging players in the NASH/MASH treatment market. Its role is important because China and Asia Pacific will become larger opportunities as metabolic disease prevalence rises and liver disease screening improves.

The company gives the market a regional development angle. Western companies may dominate early global launch discussions, but local and regional pharma players can influence adoption in China, especially where pricing, reimbursement and domestic trial data matter.

The opportunity is large. The challenge is whether domestic assets can compete clinically and commercially with global drugs entering Asian markets.

Eli Lilly

Eli Lilly is not listed among DataM’s major player group on the page, but it is difficult to ignore in MASH because of tirzepatide interest. DataM notes that tirzepatide has created strong attention through Phase 2 results in MASH resolution and fibrosis improvement.

Lilly’s strength is obvious. It has one of the strongest metabolic disease franchises in the world. If tirzepatide continues to show liver benefit, Lilly could become a major force in MASH without needing to build the category from scratch.

The uncertainty is indication strategy, trial design and payer positioning. A metabolic drug with liver benefit is powerful, but MASH approval and adoption still require liver specific evidence.

Viking Therapeutics

Viking Therapeutics belongs in the competitive discussion because it has been active in metabolic and liver disease drug development. Its thyroid hormone receptor beta work has made it relevant to the broader MASH mechanism landscape.

The company’s appeal is mechanism familiarity. Resmetirom has validated the THR beta pathway commercially. That can help competitors with similar or adjacent approaches because physicians and investors now have a reference point.

The challenge is entering after Madrigal. A later THR beta player needs to show meaningful differentiation in efficacy, safety, dosing, tolerability or patient selection. Otherwise, first mover advantage will be hard to overcome.

Competitor Analysis: Top NASH/MASH Treatment Market Players

Request for Exclusive Sample on NASH/MASH Treatment Market 

The table shows the market split. Madrigal owns the first approved liver directed position. Novo Nordisk and Eli Lilly bring metabolic scale. Boehringer is building an incretin based competitor. Akero and 89bio are betting on FGF21. Inventiva, Sagimet and Viking are trying to win through differentiated mechanisms. Chia Tai Tianqing brings regional relevance.

Who Are Other Companies Influencing the Market?

Several companies outside the top ten still matter. Gilead Sciences has long been associated with liver disease development, even though MASH has been a difficult field for large pharma. Terns Pharmaceuticals, 3V Bio, Galectin Therapeutics and other smaller companies continue to influence the pipeline conversation through differentiated targets and fibrosis related approaches.

Diagnostics companies also matter more than they usually get credit for. DataM identifies non invasive diagnosis linked treatment initiation as a fast growing use case because most MASH patients remain undiagnosed until advanced disease. FibroScan, blood based fibrosis scores, imaging tools and biomarker panels will influence how many patients enter treatment pathways.

Specialty pharmacy providers and payer support vendors will also shape the market. MASH treatment will not behave like a simple primary care prescription market at first. Prior authorization, fibrosis confirmation, monitoring, adherence support and specialist coordination will all affect uptake.

Obesity and diabetes companies are indirect competitors as well. MASH overlaps heavily with metabolic disease. Any company that controls obesity or diabetes treatment pathways can influence which patients are identified, referred and eventually treated for liver disease.

What Is Driving Competition in the Market?

Competition is being driven by the F2 to F3 fibrosis population. That is the commercial center. DataM identifies Stage 2 to 3 fibrosis treatment as one of the fastest growing use cases because it represents the clearest intervention window before cirrhosis.

Diagnosis is the second driver. The market will not grow only because drugs exist. It needs patients to be found. That means non invasive testing, risk based screening in obesity and diabetes clinics, referral pathways and payer approved diagnostic criteria.

The third driver is mechanism fit. Liver directed therapies, GLP 1 drugs, GLP 1 glucagon agonists, FGF21 analogs, FASN inhibitors and THR beta agents will not all serve the same patient type. Some patients will be treated mainly because of fibrosis risk. Others will be treated because metabolic dysfunction is the dominant clinical problem.

Payer access may become the hardest competitive barrier. The eligible patient population is large, therapy duration may be long and outcomes take time to prove. Payers will likely favor drugs with clear fibrosis benefit, strong safety, measurable response markers and evidence that treatment reduces downstream cirrhosis, transplant and liver failure costs.

Physician adoption will also split. Hepatologists will lead early use in advanced fibrosis. Gastroenterologists will expand the diagnosed pool. Endocrinologists may become more influential as GLP 1 based treatment connects MASH care to obesity and diabetes.

The market will favor companies that combine clinical evidence with market access execution. A good drug will not be enough. The winners will need diagnostic support, prescriber education, payer strategy and a clear patient selection story.

Read Complete Research Report: https://www.datamintelligence.com/research-report/nash-or-mash-treatment-market